<DOC>
	<DOCNO>NCT02776683</DOCNO>
	<brief_summary>The objective trial evaluate safety tolerability BI 695502 combination leucovorin/5-fluorouracil/oxaliplatin ( mFOLFOX6 ) maintenance therapy ( applicable ) . As well evaluate follow efficacy parameter : Progression-free survival ( PFS ) , objective response rate ( proportion patient complete response [ CR ] plus partial response [ PR ] ) , overall survival ( OS ) , duration response ( DOR ) , time progression ( TTP ) .</brief_summary>
	<brief_title>Open-label , Single Arm Trial BI 695502 Patients With Previously Untreated Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Inclusion criterion : Males female age &gt; =18 year ( Japan : Age &gt; =20 year time signing Informed Consent Form ) histologically confirm metastatic colorectal cancer ( mCRC ) . Metastatic disease amenable surgical curative treatment eligible receive therapy mFOLFOX6 ( Leucovorin/5Fluorouracil/Oxaliplatin ) + bevacizumab . At least one measurable lesion accord Response Evaluation Criteria Solid Tumors ( RECIST ) 1.1 . Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 1 . Adequate hepatic , renal bone marrow function . Further inclusion criterion apply . Exclusion criterion : Prior systemic therapy metastatic disease Prior therapy monoclonal antibody small molecule inhibitor Vascular endothelial growth factor ( VEGF ) VEGF receptor , include Avastin® Avastin® biosimilar Previous malignancy Colorectal cancer ( CRC ) last 5 year except basal cell cancer skin preinvasive cancer cervix Spinal cord compression brain metastasis unless asymptomatic , stable require steroid least 6 week prior start study treatment Any unresolved toxicity &gt; Common Toxicity Criteria Grade 1 ( except alopecia ) previous anticancer therapy ( include radiotherapy ) History evidence inherit bleed diathesis coagulopathy risk bleed A thrombotic hemorrhagic event &lt; =6 month prior screen ( include hemoptysis , Gastrointestinal ( GI ) bleeding , hematemesis , central nervous system hemorrhage , epistaxis , vaginal bleeding , cerebral infarction , transient ischemic attack , myocardial infarction , angina , coronary artery disease ) Further exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>